COMMON INITIAL DOSING REGIMENS

• A common protocol is 5–10 mg subcutaneously once daily for 10–20 consecutive days, repeated every 3–6 months. Some regimens use shorter or longer cycles depending on individual response and therapeutic goals.

MECHANISM OF ACTION

• Epitalon (also known as epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that mimics a naturally occurring peptide produced in the pineal gland. It is believed to act on the hypothalamic-pituitary axis to help regulate melatonin secretion, circadian rhythm, and possibly support DNA repair by upregulating telomerase activity. It may also have antioxidant effects and modulate gene expression involved in cellular senescence and aging.

COMMON SIDE EFFECTS

• General: Restlessness, vivid dreams, fatigue, or mild euphoria.

• Neurologic: Headache, dizziness, or changes in sleep pattern.

• Injection Site: Mild redness, swelling, or irritation.

• Rare: Allergic reactions or gastrointestinal upset.

CONTRAINDICATIONS

• Absolute: Known hypersensitivity to Epitalon or any of its excipients.

• Relative: Use with caution in individuals with active malignancy, as theoretical concerns exist regarding telomerase activation and tumor promotion.

COMPARISON WITH OTHER AGENTS

• Melatonin: Both melatonin and Epitalon may improve sleep and circadian rhythm regulation. Epitalon may offer broader systemic effects including potential telomere maintenance.

• NAD+ precursors (e.g., NMN, NR): These also target cellular aging pathways, primarily via mitochondrial function and sirtuin activation, whereas Epitalon appears to work through telomerase modulation and pineal gland activity.

• Thymic peptides: Similar to thymosin alpha-1 or thymosin beta-4, Epitalon is used in the anti-aging and regenerative context, though with a different mechanism related to the pineal gland and telomerase.

EXPERIMENTAL TREATMENT DISCLAIMER:

• Epitalon is not approved by the FDA for the treatment, mitigation, or prevention of any disease. Its use is considered experimental. While preliminary studies and anecdotal reports suggest possible benefits, the long-term safety and efficacy of Epitalon have not been established in large-scale human trials. By choosing to undergo treatment with Epitalon, the patient acknowledges the experimental nature of this therapy and assumes all associated risks.

MORE INFORMATION

• FDA Safety Data Sheet not available (experimental peptide).